PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

CURRENT OPINION IN CARDIOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is an esteemed journal in the field of cardiology that has been serving the academic community since 1988. With a robust focus on the latest developments and emerging trends in cardiovascular medicine, this journal aims to bridge the gap between clinical practice and research, offering critical insights and expert commentary. The journal is recognized in the medical community, achieving a 2023 Scopus rank of #148 out of 387 in its category, placing it in the 61st percentile. Although it operates under a subscription-based model, CURRENT OPINION IN CARDIOLOGY remains an essential resource for researchers, practitioners, and students seeking cutting-edge knowledge and advancements in cardiology. As a Q2 journal in the field, it continues to foster dialogue and provide a platform for disseminating impactful cardiovascular research, ultimately contributing to improved patient outcomes and informed clinical decisions.

Cardio-Oncology, published by BMC since 2015, serves as a premier open-access journal dedicated to the intersection of cardiology and oncology, ensuring that vital research reaches a global audience without barriers. With an impactful presence in the United Kingdom and an impressive Q1 ranking in Cardiology and Cardiovascular Medicine, alongside a Q2 ranking in Oncology as of 2023, the journal captures the growing importance of managing cardiovascular health in cancer patients. Aimed at researchers, healthcare professionals, and students, Cardio-Oncology publishes high-quality research, reviews, and clinical studies that advance understanding in this critical field, fostering an interdisciplinary dialogue essential for improving patient outcomes. Accessible and relevant, the journal reflects the concerted effort to bridge gaps in knowledge and address the complexities faced by healthcare providers managing the dual challenges of cancer and cardiovascular disease.

Nepalese Heart Journal, published by the CARDIAC SOC NEPAL, serves as a premier platform for disseminating knowledge in the field of cardiology and cardiovascular health. With an ISSN of 2091-2978, this journal aims to bridge the gap between researchers, clinicians, and academicians by presenting high-quality, peer-reviewed articles that address clinical practices, innovative research, and emerging trends in heart disease management, especially within the context of Nepal and the surrounding region. Although it operates under a traditional publishing model, its commitment to excellence aids in reinforcing the scientific discourse in an area critical to public health. The journal is a valuable resource for professionals and students alike who are focused on advancing their understanding of cardiology and its implications for health policy and practice. Exploring the intersections of local challenges and global advancements in heart health, the Nepalese Heart Journal is poised to contribute meaningfully to the evolving landscape of cardiovascular research.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

Kardiologia Polska, the esteemed journal of the Polish Cardiac Society, has established itself as a vital resource in the field of cardiology and cardiovascular medicine since its inception in 1954. With an ISSN of 0022-9032 and an E-ISSN of 1897-4279, this journal serves as a platform for groundbreaking research and scholarly articles that contribute to the advancement of heart health. Although currently not an open access journal, it remains an essential reference for practitioners and researchers seeking to stay abreast of the latest developments in cardiovascular science. The journal reflects its scholarly depth through a Category Quartile of Q3 and a commendable Scopus ranking at the 48th percentile in its field. Published primarily in Poland, it caters to a global audience eager to explore comprehensive studies spanning clinical cardiology, innovative therapeutic approaches, and emerging cardiovascular trends. Join a thriving academic community by engaging with the invaluable insights and research contributions found within the pages of Kardiologia Polska.

Cardiovascular Toxicology is a pivotal journal dedicated to advancing the understanding of the interplay between toxic substances and cardiovascular health. Published by HUMANA PRESS INC, this journal serves as a critical resource for researchers and professionals in the fields of cardiology, toxicology, and molecular biology. With an ISSN of 1530-7905 and an E-ISSN of 1559-0259, it has established itself as a key source of high-quality research since its inception in 2001, continuing to contribute valuable insights through 2024. The journal enjoys a robust reputation, evidenced by its Q2 ranking in both Cardiology and Cardiovascular Medicine and Toxicology, along with a Q3 ranking in Molecular Biology for 2023. With Scopus rankings placing it in the 80th percentile for Cardiology and 71st for Toxicology, Cardiovascular Toxicology attracts submissions that reflect cutting-edge research and innovative methodologies. Notably, the journal prioritizes stringent peer review and scholarly rigor, ensuring that published works significantly impact the understanding of cardiovascular responses to various toxic agents. Though not an open-access journal, its content remains highly sought after in a diverse scholarly community, making it indispensable for those dedicated to enhancing cardiovascular disease prevention, diagnosis, and treatment through toxicological insights.

Arquivos Brasileiros de Cardiologia is a leading open-access journal dedicated to advancing the field of cardiology and cardiovascular medicine. Established in 1950 and published by the ARQUIVOS BRASILEIROS CARDIOLOGIA, this Brazilian journal plays a crucial role in disseminating high-quality research that addresses both emerging and established topics in cardiovascular science. With an impressive history and a commitment to open access since 1997, it provides researchers, healthcare professionals, and students with free and readily available content that significantly contributes to the understanding and management of cardiovascular diseases. The journal is indexed in Scopus and holds a Q3 ranking in the category of Cardiology and Cardiovascular Medicine, demonstrating its relevance and participation within the global research community. Researchers can submit their work and access a wealth of information that spans a variety of subfields, reflecting the journal’s dedication to fostering innovation and collaboration within cardiology. With a mailing address at Avenida Marechal Câmara, 160-330 Centro, Rio de Janeiro, RJ 20,020-907, Brazil, the journal continues to serve as a vital platform for scholarly communication and knowledge exchange in the cardiovascular realm.

Journal of Cardiovascular Development and Disease, an esteemed publication by MDPI, has been a dedicated platform for disseminating cutting-edge research since its inception in 2014. Based in Switzerland, this Open Access journal not only provides unrestricted access to its content but also fosters global collaboration among scholars focusing on cardiovascular health and disease development. With an impressive focus classified as Q1 in Pharmacology, Toxicology and Pharmaceutics for 2023, it attracts a diverse range of interdisciplinary research, supporting advancements in pharmacological applications relevant to cardiac conditions. The journal's ongoing convergence through 2024 highlights its commitment to the evolving landscape of cardiovascular research, making it a vital resource for researchers, professionals, and students alike who are keen to contribute to and learn from significant developments in this critical field.